Odyssean LLC Raises Stock Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Odyssean LLC grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 201.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 41,394 shares of the company’s stock after acquiring an additional 27,657 shares during the quarter. Odyssean LLC owned about 0.09% of Tarsus Pharmaceuticals worth $2,605,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after buying an additional 127,470 shares in the last quarter. TimesSquare Capital Management LLC raised its position in shares of Tarsus Pharmaceuticals by 24.3% during the 4th quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after buying an additional 64,941 shares in the last quarter. Bank of America Corp DE raised its position in shares of Tarsus Pharmaceuticals by 57.5% during the 1st quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after buying an additional 436,271 shares in the last quarter. D.A. Davidson & CO. purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $1,493,000. Finally, Ishara Investments LP bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $1,965,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $71.45 on Wednesday. The stock has a market cap of $3.14 billion, a PE ratio of -65.55 and a beta of 0.53. Tarsus Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $85.25. The company has a 50-day moving average price of $63.88 and a 200 day moving average price of $65.18. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). The firm had revenue of $173.91 million during the quarter, compared to analysts’ expectations of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. Equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Mizuho decreased their price objective on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Guggenheim lowered their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $90.50.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the transaction, the director owned 106,786 shares of the company’s stock, valued at $6,633,546.32. This represents a 10.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Farrow sold 14,396 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.95, for a total value of $877,436.20. Following the completion of the transaction, the insider directly owned 56,801 shares in the company, valued at $3,462,020.95. This trade represents a 20.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 39,850 shares of company stock valued at $2,452,821. Corporate insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.